Pimavanserin,
developed by San Diego-based Acadia Pharmaceuticals, is a
selective and potent serotonin 2A (5-HT2A) receptor inverse
agonist. The USFDA approved this once-daily drug to treat
the delusions and hallucinations associated with psychosis as a
function of Parkinson’s disease. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving
as a selective inverse agonist of the serotonin 5-HT2A receptor
while exhibiting 40-fold selectivity over the 5-HT2C receptor
and having no significant affinity or activity with the 5-HT2B or
dopamine receptors.